The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

Background. Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. Methods. We enrolled 17,622...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2009

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/22373

Acceso en línea:

https://doi.org/10.1086/597307
https://repository.urosario.edu.co/handle/10336/22373

Palabra clave:

Placebo
Wart virus vaccine
Wart virus vaccine
Adolescent
Adult
Article
Cancer prevention
Clinical trial
Condyloma acuminatum
Controlled clinical trial
Controlled study
Disease duration
Double blind procedure
Drug efficacy
Female
Human
Human papillomavirus type 11
Human papillomavirus type 16
Human papillomavirus type 18
Human papillomavirus type 31
Human papillomavirus type 45
Human papillomavirus type 6
Infection prevention
Major clinical study
Papanicolaou test
Phase 3 clinical trial
Priority journal
Randomized controlled trial
Uterine cervix biopsy
Uterine cervix cancer
Uterine cervix carcinoma in situ
Uterine cervix cytology
Vaccination
Alphapapillomavirus
Classification
Genetics
Immunology
Uterine cervix tumor
Virology
Virus infection
Adolescent
Adult
Alphapapillomavirus
Female
Humans
Papillomavirus infections
Papillomavirus vaccines
Uterine cervical neoplasms
Young adult

Rights

License

Abierto (Texto Completo)